Search Results - "KURUVILLA, J"

A systematic review of contemporary phase I trials in patients with lymphoma by Griguolo, G., Zorzi, M.F., Pirosa, M.C., Treglia, G., Bertoni, F., Kuruvilla, J., Zucca, E., Stathis, A.

“…We performed a systematic review of phase I trials specifically designed for lymphoma patients. PubMed and Cochrane Library databases were searched using…”
Get full text

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial by Witzig, T.E., Tobinai, K., Rigacci, L., Ikeda, T., Vanazzi, A., Hino, M., Shi, Y., Mayer, J., Costa, L.J., Bermudez Silva, C.D., Zhu, J., Belada, D., Bouabdallah, K., Kattan, J.G., Kuruvilla, J., Kim, W.S., Larouche, J.-F., Ogura, M., Ozcan, M., Fayad, L., Wu, C., Fan, J., Louveau, A.-L., Voi, M., Cavalli, F.

“…Patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI)≥3 are at higher risk for relapse after a complete response…”
Get full text

COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS by Gong, I. Y., Aminilari, M., Landego, I., Hueniken, K., Zhou, Q., Hodgson, D. C., Kuruvilla, J.

Get full text

Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND) by Sehn, L. H., Kuruvilla, J., Salles, G., Maddocks, K. J., Koch, C., Xue, Z., Amoloja, T., Amin, A., Duell, J.

Get full text

Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation by Mayo, Samantha J., Messner, Hans A., Rourke, Sean B., Howell, Doris, Victor, J. Charles, Lipton, Jeffrey H., Kuruvilla, J., Gutpa, Vikas, Kim, Dennis Dong Hwan, Michelis, Fotios V., Metcalfe, Kelly

“…Certain subgroups of patients may be particularly vulnerable to cognitive decline after treatment with allogeneic hematopoietic stem cell transplant (HCT). The…”
Get full text

CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA by Manji, F., Bhella, S., Kridel, R., Kukreti, V., Kuruvilla, J., Prica, A., Crump, M.

Get full text

The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD by Uhm, J, Hamad, N, Michelis, F V, Shanavas, M, Kuruvilla, J, Gupta, V, Lipton, J H, Messner, H A, Seftel, M, Kim, D D

“…Hemorrhagic cystitis (HC) is a common complication after allogeneic hematopoietic SCT (allo-HSCT). Several risk factors have been suggested including…”
Get full text

Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial by Villa, D., Larouche, J. F., Cheung, M., Keating, M. M., Zukotynski, K., Tonseth, P., Mayo, S., Laister, R., Scott, D., Kuruvilla, J.

Get full text

CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy by Assouline, S., Villa, D., Hay, A., Johnson, N., Crump, M., Kridel, R., Prica, A., Shamy, A., Gerrie, A., Savage, K., Kelly, J., Shepherd, L., Chen, B., Kuruvilla, J., Manji, F.

Get full text

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients by Bhimji, A., Bhaskaran, A., Singer, L.G., Kumar, D., Humar, A., Pavan, R., Lipton, J., Kuruvilla, J., Schuh, A., Yee, K., Minden, M.D., Schimmer, A., Rotstein, C., Keshavjee, S., Mazzulli, T., Husain, S.

“…Exhaled breath condensate (EBC) is a noninvasive means of sampling the airways that has shown significant promise in the diagnosis of many disorders. There…”
Get full text

Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation by Villa, D., Crump, M., Keating, A., Panzarella, T., Feng, B., Kuruvilla, J.

“…The proportion of potentially eligible patients with transformed indolent non-Hodgkin lymphoma who undergo autologous stem-cell transplantation (ASCT) is…”
Get full text

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning by Shanavas, M, Messner, H A, Atenafu, E G, Kim, D H, Kuruvilla, J, Lipton, J H, Uhm, J, Seftel, M, Alam, N, Gupta, V

“…Graft failure is one of the major barriers to the success of allogeneic hematopoietic cell transplantation (HCT) in myelofibrosis (MF). We report our…”
Get full text

Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT by (Dong Hwan) Kim, D, Al-Dawsari, G, Chang, H, Panzarella, T, Gupta, V, Kuruvilla, J, Lipton, J H, Messner, H A

“…A total of 418 patients receiving hematopoietic SCT and surviving beyond day 100 were examined for the occurrence of large granular lymphocytes (LGLs). LGL…”
Get full text

PHASE I STUDY OF THE CD19/CD3 HALF‐LIFE EXTENDED BITE ® MOLECULE AMG 562 IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA by Mead, M. D., Popplewell, L. L., Subklewe, M., Ghobadi, A., Kuruvilla, J., Kimball, A., Tuglus, C., Agarwal, S., Stieglmaier, J.

Get full text

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2 by Michelis, F V, Messner, H A, Atenafu, E G, McGillis, L, Lambie, A, Uhm, J, Alam, N, Seftel, M D, Gupta, V, Kuruvilla, J, Lipton, J H, Kim, D D

“…For AML, older age, advanced disease and increased hematopoietic cell transplant comorbidity index (HCT-CI) are associated with worse prognosis following…”
Get full text

An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment by Lavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., Marinello, P., Timmerman, J.

Get full text

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY by Sehn, L. H., Bartlett, N. L., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Fay, K., Ku, M., Nastoupil, L., Wei, M. C., Yin, S., To, I., Hu, N., Min, J., Penuel, E., Belousov, A., Coimbra, A., Jemaa, S., Bender, B., Turner, D., Budde, L. E.

Get full text

Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation by Mayo, S, Messner, H A, Rourke, S B, Howell, D, Victor, J C, Kuruvilla, J, Lipton, J H, Gupta, V, Kim, D D, Piescic, C, Breen, D, Lambie, A, Loach, D, Michelis, F V, Alam, N, Uhm, J, McGillis, L, Metcalfe, K

“…Although neurocognitive impairment has been established as a major issue among cancer survivors, the real-world consequences of this impairment are unclear…”
Get full text

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission by Michelis, F V, Atenafu, E G, Gupta, V, Kim, D D, Kuruvilla, J, Lipton, J H, Loach, D, Seftel, M D, Uhm, J, Alam, N, Lambie, A, McGillis, L, Messner, H A

“…Secondary AML (sAML) has a poor prognosis with conventional chemotherapy alone. Allogeneic hematopoietic cell transplantation (HCT) is beneficial for high-risk…”
Get full text

FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS – A PROSPECTIVE PILOT STUDY by Prica, A., Dhir, V., Maganti, M., Kukreti, V., Kuruvilla, J., Crump, M.

Get full text